Profile data is unavailable for this security.
About the company
Clinical Laserthermia Systems AB is a Sweden-based company active in the medical equipment industry. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The Company's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.
- Revenue in SEK (TTM)18.63m
- Net income in SEK-64.20m
- Incorporated2006
- Employees7.00
- LocationClinical Laserthermia Systems ABScheelev. 2, building 405LUND 223 81SwedenSWE
- Phone+46 46152100
- Websitehttps://clinicallaser.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBS-Bioactive Bone Substitutes Oyj | 0.00 | -41.19m | 28.58m | -- | -- | 0.5269 | -- | -- | -0.2069 | -0.2069 | 0.00 | 0.1765 | 0.00 | -- | -- | -- | -35.38 | -25.12 | -45.41 | -28.54 | -- | -- | -- | -- | -- | -27.51 | 0.5953 | -- | -- | -- | -12.64 | -- | -- | -- |
| ProstaLund AB | 16.22m | -19.84m | 28.67m | 7.00 | -- | 0.4951 | -- | 1.77 | -0.2328 | -0.2328 | 0.1807 | 0.4706 | 0.243 | 0.3281 | 6.67 | -- | -29.73 | -29.14 | -33.53 | -35.01 | 70.50 | 75.26 | -122.35 | -68.94 | 2.60 | -135.86 | 0.0175 | -- | 27.54 | 10.36 | -53.27 | -- | 20.35 | -- |
| Inhalation Sciences Sweden AB | 15.48m | -3.93m | 31.55m | 8.00 | -- | 2.81 | -- | 2.04 | -0.2796 | -0.2796 | 1.09 | 0.7409 | 0.8096 | 0.6328 | 4.37 | 1,935,000.00 | -20.53 | -27.93 | -29.23 | -43.82 | 86.29 | 71.13 | -25.36 | -48.02 | 2.81 | -6.49 | 0.0639 | -- | 43.55 | 26.33 | 60.87 | -- | -- | -- |
| Bio Vitos Pharma AB | 1.01m | -15.13m | 32.78m | 1.00 | -- | 0.8735 | -- | 32.43 | -0.7859 | -0.7859 | 0.0393 | 0.9525 | 0.0271 | 0.2064 | 19.99 | 1,010,830.00 | -40.53 | -31.11 | -54.83 | -32.92 | 89.68 | -- | -1,496.73 | -1,026.76 | 2.28 | -- | 0.00 | -- | 126.97 | -- | 13.64 | -- | -- | -- |
| PMD Device Solutions AB | 51.91m | -43.42m | 33.21m | 37.00 | 0.2528 | -- | -- | 0.6397 | 5.06 | 5.06 | 3.54 | -5.52 | 0.8624 | -- | 4.47 | -- | -72.13 | -- | -- | -- | 82.86 | -- | -83.64 | -- | 0.1121 | -1.88 | -- | -- | -- | -- | -- | -- | -- | -- |
| Scandinavian ChemoTech AB | 5.03m | -15.70m | 37.74m | 5.00 | -- | 4.53 | -- | 7.50 | -0.8655 | -0.8655 | 0.2647 | 0.384 | 0.3162 | 0.5947 | 1.37 | 838,666.70 | -98.64 | -87.29 | -98.64 | -118.55 | 29.67 | 252.05 | -311.96 | -2,122.77 | -- | -22.93 | 0.00 | -- | 496.62 | 19.13 | 7.28 | -- | -- | -- |
| Scandinavian Real Heart AB | 0.00 | -75.02m | 37.85m | 12.00 | -- | 0.4136 | -- | -- | -51.82 | -51.82 | 0.00 | 44.25 | 0.00 | -- | -- | 0.00 | -73.46 | -24.27 | -87.03 | -26.81 | -- | 832.41 | -- | -6,070.11 | -- | -700.38 | 0.1023 | -- | -100.00 | -- | -385.97 | -- | -25.76 | -- |
| Phase Holographic Imaging PHI AB | 9.12m | -21.81m | 52.19m | 14.00 | -- | -- | -- | 5.72 | -0.8695 | -0.8695 | 0.3634 | -0.0273 | 0.2373 | 0.6598 | 1.18 | 651,571.40 | -56.73 | -62.04 | -88.25 | -79.16 | 71.06 | 63.16 | -239.04 | -328.50 | 0.1916 | -5.61 | 1.04 | -- | 6.16 | 17.96 | 12.98 | -- | 22.76 | -- |
| Clinical Laserthermia Systems AB | 18.63m | -64.20m | 52.65m | 7.00 | -- | 0.862 | -- | 2.83 | -7.93 | -7.93 | 2.05 | 4.39 | 0.265 | 7.62 | 5.22 | -- | -92.16 | -123.49 | -103.14 | -312.95 | -175.42 | -1,084.16 | -347.76 | -1,625.03 | 2.39 | -11.71 | 0.0077 | -- | 31.99 | 35.55 | -12.92 | -- | 18.26 | -- |
| iZafe Group AB | 6.29m | -31.99m | 55.00m | 7.00 | -- | 3.53 | -- | 8.75 | -0.1319 | -0.1319 | 0.0259 | 0.0567 | 0.1602 | 3.25 | 12.26 | 898,285.70 | -81.49 | -52.17 | -100.43 | -69.40 | -116.33 | -198.20 | -508.73 | -487.50 | 0.4406 | -43.46 | 0.3159 | -- | 149.93 | -24.79 | -36.76 | -- | -41.66 | -- |
| ScandiDos AB | 61.35m | -9.67m | 74.80m | 26.00 | -- | 2.14 | -- | 1.22 | -0.2068 | -0.2068 | 1.26 | 0.766 | 0.8184 | 1.31 | 6.88 | 1,978,871.00 | -12.90 | -12.60 | -23.54 | -21.76 | 50.39 | 51.58 | -15.76 | -15.37 | 0.9476 | -6.36 | 0.00 | -- | -1.82 | 4.36 | -60.62 | -- | -19.29 | -- |
Data as of Nov 22 2024. Currency figures normalised to Clinical Laserthermia Systems AB's reporting currency: Swedish Krona SEK
0.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Oct 2024 | 3.69k | 0.03% |
| Evli Fund Management Co. Ltd.as of 30 Aug 2024 | 908.00 | 0.01% |
Data from 31 Oct 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
